The Use of Immunoglobulin Therapy for Patients Undergoing Solid Organ Transplantation: An Evidence-Based Practice Guideline

Transfusion Medicine Reviews

Volumn 24, Issue SUPPL. 1, 2010, Pages

  Shehata, Nadine ^{a,b,c,d,e,f,g,h,i,j}   Palda, Valerie A ^{a,b,c,d,e,f,g,h,i,j}   Meyer, Ralph M ^{a,b,c,d,e,f,g,h,i,j}   Blydt Hansen, Tom D ^{a,b,c,d,e,f,g,h,i,j}   Campbell, Patricia ^{a,b,c,d,e,f,g,h,i,j}   Cardella, Carl ^{a,b,c,d,e,f,g,h,i,j}   Martin, Steven ^{a,b,c,d,e,f,g,h,i,j}   Nickerson, Peter ^{a,b,c,d,e,f,g,h,i,j}   Peltekian, Kevork ^{a,b,c,d,e,f,g,h,i,j}   Ross, Heather ^{a,b,c,d,e,f,g,h,i,j}   Waddell, Tom K ^{a,b,c,d,e,f,g,h,i,j}   West, Lori ^{a,b,c,d,e,f,g,h,i,j}   Anderson, David ^{a,b,c,d,e,f,g,h,i,j}   Freedman, John ^{a,b,c,d,e,f,g,h,i,j}   Hume, Heather ^{a,b,c,d,e,f,g,h,i,j}  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

^c UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^d UNIVERSITY OF MANITOBA   (Canada)

^e CHILDREN S HOSPITAL RESEARCH INSTITUTE OF MANITOBA   (Canada)

^f UNIVERSITY OF ALBERTA   (Canada)

^g UNIVERSITY HEALTH NETWORK   (Canada)

^h UNIVERSITY OF MONTREAL   (Canada)

ⁱ ST MICHAEL'S HOSPITAL   (Canada)

^j DALHOUSIE UNIVERSITY   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; CARIMUNE; CD20 ANTIBODY; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOMEGALOVIRUS ANTIBODY; DACLIZUMAB; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; MEPREDNISONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PLACEBO; PREDNISONE; RAPAMYCIN; RITUXIMAB; SIMVASTATIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ARTHRALGIA; ARTICLE; ASEPTIC MENINGITIS; BACTERIAL INFECTION; BLOOD GROUP ABO INCOMPATIBILITY; CARDIAC GRAFT REJECTION; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; FEVER; GRAFT SURVIVAL; HEADACHE; HEART INFARCTION; HEART TRANSPLANTATION; HEMOLYTIC ANEMIA; HUMAN; IMMUNE COMPLEX DISEASE; IMMUNOGLOBULIN DEFICIENCY; IMMUNOTHERAPY; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LOW DRUG DOSE; LUNG TRANSPLANTATION; MACULOPAPULAR RASH; MYCOSIS; ORGAN TRANSPLANTATION; PERIOPERATIVE PERIOD; PLASMAPHERESIS; SIDE EFFECT; SINGLE DRUG DOSE; SURVIVAL RATE; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME; VIRUS INFECTION;

EID: 71249110321     PISSN: 08877963     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tmrv.2009.09.010     Document Type: Article

References (75)

1. Nahirniak S., and Hume H. Guidelines for the use of intravenous immune globulin for primary immune deficiency and solid organ transplantation. Transfus Med Rev 24 Suppl 1 (2010) S1-S6
2. Anderson D., Ali K., Blanchette V., et al. Guidelines on the use of intravenous immune globulin for hematologic conditions. Transfus Med Rev 21 2 Suppl 1 (2007) S9-S56
3. Feasby T., Banwell B., Benstead T., et al. Guidelines on the use of intravenous immune globulin for neurologic conditions. Transfus Med Rev 21 2 Suppl 1 (2007) S57-S107
4. Shehata N., Palda V., Bowen T., et al. The use of immunoglobulin therapy for patients with primary immune deficiency: An evidence-based practice guideline. Transfus Med Rev 24 Suppl 1 (2010) S28-S50
5. Staak A., Renner F., Suesal C., et al. Immunoglobulin induction therapy in renal transplant recipients: Effects on immunoglobulin and regulatory antibody levels. Transplant Proc 38 (2008) 3483-3485
6. Bunchman T.E., Parekh R.S., Kershaw D., et al. Beneficial effect of Sandoglobulin upon allograft survival in the pediatric renal transplant recipient. Clin Transpl 11 (1997) 604-607
7. Meyer S.R., Ross D.B., Forbes K., et al. Failure of prophylactic intravenous immunoglobulin to prevent sensitization to cryopreserved allograft tissue used in congenital cardiac surgery. J Thorac Cardiovasc Surg 133 (2007) 1517-1523
8. Drakos S., Kfoury A., Long J.W., et al. Low-dose prophylactic intravenous immunoglobulin does not prevent HLA sensitization in left ventricular assist device recipients. Ann Thorac Surg 82 (2006) 889-894
9. Montgomery R.A., and Locke J.E. ABO-incompatible transplantation: Less may be more. Transplantation 84 12 Suppl (2007) S8-S9
10. Jordan S.C., Tyan D., Stablein D., et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: Report of the NIH IG02 trial. J Am Soc Nephrol 15 (2004) 3256-3262
11. Peraldi M.N., Akposso K., Haymann J.P., et al. Long-term benefit of intravenous immunoglobulins in cadaveric kidney retransplantation. Transplantation 62 (1996) 1670-1673
12. Anglicheau D., Loupy A., Suberbielle C., et al. Posttransplant prophylactic intravenous immunoglobulin in kidney transplant patients at high immunological risk: A pilot study. Am J Transplant 7 (2007) 1185-1192
13. Bielmann D., Honger G., Lutz D., et al. Pretransplant risk assessment in renal allograft recipients using virtual crossmatching. Am J Transplant 7 (2007) 626-632
14. Mahmoud K.M., Sobh M.A., El S.F., et al. Management of sensitized patients awaiting renal transplantation: does sequential therapy of intravenous immunoglobulin and simvastatin offer a solution?. Eur J Pharmacol 561 (2007) 202-205
15. Stegall M.D., Gloor J., Winters J.L., et al. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 6 (2006) 346-351
16. Thielke J., DeChristopher P.J., Sankary H., et al. Highly successful living donor kidney transplantation after conversion to negative of a previously positive flow-cytometry cross-match by pretransplant plasmapheresis. Transplant Proc 37 (2005) 643-644
17. Akalin E., Ames S., Sehgal V., et al. Intravenous immunoglobulin and thymoglobulin induction treatment in immunologically high-risk kidney transplant recipients. Transplantation 79 (2005) 742
18. Mahmoud K., Sobh M., El-Shenawy F., et al. Effect of high-dose intravenous immunoglobulin on suppression of alloantibodies against HLA in highly sensitized transplant candidates. Transplant Proc 36 (2004) 1850-1852
19. Akalin E., Ames S., Sehgal V., et al. Intravenous immunoglobulin (IVIG) and thymoglobulin facilitate kidney transplantation in complement dependent cytotoxicity (CDC) B cell and flow cytometry (FC) T and/or B cell cross-match positive patients. Transplantation 76 (2003) 1444-1447
20. Gloor J.M., DeGoey S.R., Pineda A.A., et al. Overcoming a positive crossmatch in living-donor kidney transplantation. Am J Transplant 3 (2003) 1017-1023
21. Jordan S.C., Vo A., Bunnapradist S., et al. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 76 (2003) 631-636
22. Zachary A.A., Montgomery R.A., Ratner L.E., et al. Specific and durable elimination of antibody to donor HLA antigens in renal-transplant patients. Transplantation 76 (2003) 1519-1525
23. Glotz D., Antoine C., Julia P., et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant 2 (2002) 758-760
24. Sonnenday C.J., Ratner L.E., Zachary A.A., et al. Preemptive therapy with plasmapheresis/intravenous immunoglobulin allows successful live donor renal transplantation in patients with a positive cross-match. Transplant Proc 34 (2002) 1614-1616
25. Schweitzer E.J., Wilson J.S., Fernandez-Vina M., et al. A high panel-reactive antibody rescue protocol for cross-match-positive live donor kidney transplants. Transplantation 70 (2000) 1531-1536
26. Glotz D., Haymann J.P., Niaudet P., et al. Successful kidney transplantation of immunized patients after desensitization with normal human polyclonal immunoglobulins. Transplant Proc 27 (1995) 1038-1039
27. Tyden G., Donauer J., Wadstrom J., et al. Implementation of a protocol for ABO-incompatible kidney transplantation-A three-center experience with 60 consecutive transplantations. Transplantation 83 (2007) 1153-1155
28. Tyden G., Kumlien G., Genberg H., et al. The Stockholm experience with ABO-incompatible kidney transplantations without splenectomy. Xenotransplantation 13 (2006) 105-107
29. Kayler L., Farber J.L., Clombe B., et al. Characterization of rejection episodes in patients following positive crossmatch and ABO-incompatible liver donor renal transplantation. Transplant International 19 (2006) 128-139
30. Tyden G., Kumlien G., Genberg H., et al. ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Am J Transplant 5 (2005) 145-148
31. Winters J.L., Gloor J.M., Pineda A.A., et al. Plasma exchange conditioning for ABO-incompatible renal transplantation. J Clin Apheresis (2004) 79-85
32. Sonnenday C.J., Warren D.S., Cooper M., Samaniego M., Haas M., King K.E., et al. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant 4 (2004) 1315-1322
33. Gloor J.M., Lager D.J., Moore S.B., et al. ABO incompatible kidney transplantation using both A2 and non-A2 living donors. Transplantation 75 (2003) 971-977
34. Casadei D.H., del C.R., Opelz G., et al. A randomized and prospective study comparing treatment with high-dose intravenous immunoglobulin with monoclonal antibodies for rescue of kidney grafts with steroid-resistant rejection. Transplantation 71 (2001) 53-58
35. Vasilescu E.R., Ho E.K., Colovai A.I., et al. Alloantibodies and the outcome of cadaver kidney allografts. Hum Immunol 67 (2006) 597-604
36. Jordan S.C., Vo A.A., Toyoda M., et al. Post-transplant therapy with high-dose intravenous gammaglobulin: Applications to treatment of antibody-mediated rejection. Pediatr Transpl 9 (2005) 155-161
37. Lehrich R.W., Rocha P.N., Reinsmoen N., et al. Intravenous immunoglobulin and plasmapheresis in acute humoral rejection: Experience in renal allograft transplantation. Hum Immunol 66 (2005) 350-358
38. White N.B., Greenstein S.M., Cantafio A.W., et al. Successful rescue therapy with plasmapheresis and intravenous immunoglobulin for acute humoral renal transplant rejection. Transplantation 78 (2004) 772-774
39. Rocha P.N., Butterly D.W., Greenberg A., et al. Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection. Transplantation 75 (2003) 1490-1495
40. Luke P.P., Scantlebury V.P., Jordan M.L., et al. Reversal of steroid- and anti-lymphocyte antibody-resistant rejection using intravenous immunoglobulin (IVIG) in renal transplant recipients. Transplantation 72 (2001) 419-422
41. Montgomery R.A., Zachary A.A., Racusen L.C., et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 70 (2000) 887-895
42. Casadei D., Rial M., Argento J., et al. Preliminary results from a randomized and prospective study of high-dose immunoglobulin versus monoclonal antibody in the rescue of steroid-resistant rejections. Transplant Proc 30 (1998) 2164
43. Jordan S.C., Quartel A.W., Czer L.S.C., et al. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral reaction in renal and cardiac allograft recipients and potential mechanism of action. Transplantation 66 (1998) 800-808
44. Casadei D., Rial M., Raimondi E., et al. Immunoglobulin i.v. high dose (IVIgHD): New therapy as a rescue treatment of grafted kidneys. Transplant Proc 28 (1996) 3290-3291
45. Leech S.H., Lopez-Cepero M., LeFor W.M., et al. Management of the sensitized cardiac recipient: The use of plasmapheresis and intravenous immunoglobulin. Clin Transplant (2006) 476-484
46. Jacobs J.P., Quintessenza J.A., Boucek R.J., et al. Pediatric cardiac transplantation in children with high panel reactive antibody. Ann Thor Surg 78 (2004) 1703-1709
47. John R., Lietz K., Schuster M., et al. Immunologic sensitization in recipients of left ventricular assist devices. J Thorac Cardiovasc Surg 125 (2003) 578-591
48. Itescu S., Burke E., Lietz K., et al. Intravenous pulse administration of cyclophosphamide is an effective and safe treatment for sensitized cardiac allograft recipients. Circulation 105 (2002) 1214-1219
49. Pisani B.A., Mullen G.M., Malinowska K., et al. Plasmapheresis with intravenous immunoglobulin G is effective in patients with elevated panel reactive antibody prior to cardiac transplantation. J Heart Lung Transplant 18 (1999) 701-706
50. John R., Lietz K., Burke E., et al. Intravenous immunoglobulin reduces anti-HLA alloreactivity and shortens waiting time to cardiac transplantation in highly sensitized left ventricular assist device recipients. Circulation 100 19 Suppl (1999) II229-II235
51. Appel III J.Z., Hartwig M.G., Davis R.D., et al. Utility of peritransplant and rescue intravenous immunoglobulin and extracorporeal immunoadsorption in lung transplant recipients sensitized to HLA antigens. Human Immunology 66 (2005) 378-386
52. Urbani L., Mazzoni A., Bianco I., et al. The role of immunomodulation in ABO-incompatible adult liver transplant recipients. J Clin Apheresis 23 (2008) 55-62
53. Vo A.A., Lukovsky M., Toyoda M., et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 359 (2008) 242-251
54. Vo A.A., Cam V., Toyoda M., et al. Safety and adverse events profiles of intravenous gammaglobulin products used for immunomodulation: A single-center experience. Clin J Am Soc Nephrol 1 (2006) 844-852
55. Assessment and management of immunological risk. A CCDT consensus forum. Available at: http://www.ccdt.ca/english/publications/final-pdfs/Immunologic-Risk.pdf0
56. Treatment of end-stage organ failure in Canada 1996 to 2005, 2007 CORR annual report. Available at: (http://secure.cihi.ca/cihiweb/dispPage.jsp?cw_page=PG_1110_E&cw_ topic=1110&cw_rel=AR_5_E)
57. End stage renal disease. Canadian Institute for Health Information. Available at : http://secure.cihi.ca/cihiweb/dispPage.jsp?cw_page=statistics_results_ topic_dialysis_e&cw_topic=Health%20Conditions&cw_subtopic=Dialysis (Accessed June 2008)
58. Laupacis A., Keown P., Pus N., et al. A study of the quality of life and cost-utility of renal transplantation. Kidney Int 50 (1996) 235-242
59. Wolfe R.A., Ashby V.B., Milford E.L., et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 341 (1999) 1725-1730
60. Karpinski M., Knoll G., Cohn A., et al. The impact of accepting living kidney donors with mild hypertension or proteinuria on transplantation rates. Am J Kidney Dis 47 (2006) 317-323
61. US. Food and Drug Adminstration. Letter to manufacturers immune globulin intravenous (human) (IGIV) required updates to product labeling. Available at:. http://www.fda.gov/cber/ltr/igiv101603.htm (Accessed June 2008)
62. Trpkov K., Campbell P., Pazderka F., et al. Pathologic features of acute renal allograft rejection associated with donor-specific antibody. Analysis using the Banff grading schema. Transplantation 61 (1996) 1586-1592
63. Petrie J.J., Rigby R.J., Hawley C.M., et al. Effect of OKT3 in steroid-resistant renal transplant rejection. Transplantation 59 (1995) 347-352
64. Nwakanma L.U., Williams J.A., Weiss E.S., et al. Influence of pre-transplant panel-reactive antibody on outcomes in 8,160 heart transplant recipients in recent era. Ann Thorac Surg 84 (2007) 1556-1562 discussion 1562-1563
65. Tambur A.R., Pamboukian S.V., Costanzo M.R., et al. The presence of HLA-directed antibodies after heart transplantation is associated with poor allograft outcome. Transplantation 80 (2005) 1019-1025
66. Pagani F.D., Dyke D.B., Wright S., et al. Development of anti-major histocompatibility complex class I or II antibodies following left ventricular assist device implantation: effects on subsequent allograft rejection and survival. J Heart Lung Transplant 20 (2001) 646-653
67. Shah A.S., Nwakanma L., Simpkins C., et al. Pretransplant panel reactive antibodies in human lung transplantation: An analysis of over 10,000 patients. Ann Thorac Surg 85 (2008) 1919-1924
68. Hadjiliadis D., Chaparro C., Reinsmoen N.L., et al. Pre-transplant panel reactive antibody in lung transplant recipients is associated with significantly worse post-transplant survival in a multicenter study. J Heart Lung Transplant 24 7 Suppl (2005) S249-S254
69. Lau C.L., Palmer S.M., Posther K.E., et al. Influence of panel-reactive antibodies on posttransplant outcomes in lung transplant recipients. Ann Thorac Surg 69 (2000) 1520-1524
70. Gammie J.S., Pham S.M., Colson Y.L., et al. Influence of panel-reactive antibody on survival and rejection after lung transplantation. J Heart Lung Transplant 16 (1997) 408-415
71. Ganschow R., Englert C., Grabhorn E., et al. Hypogammaglobulinemia in pediatric liver transplant recipients. Pediatr Transplant 9 (2005) 215-219
72. Nascimbene A., Iannacone M., Brando B., et al. Acute thrombocytopenia after liver transplant: Role of platelet activation, thrombopoietin deficiency and response to high dose intravenous IgG treatment. J Hepatol 47 (2007) 651-657
73. Echaniz-Laguna A., Battaglia F., Ellero B., et al. Chronic inflammatory demyelinating polyradiculoneuropathy in patients with liver transplantation. Muscle Nerve 30 (2004) 501-504
74. Urbani L., Mazzoni A., De Simone P., et al. Treatment of antibody-mediated rejection with high-dose immunoglobulins in ABO-incompatible liver transplant recipient. Transpl Int 20 (2007) 467-470
75. Falagas M.E., Snydman D.R., Ruthazer R., et al. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group. Clin Transplant 11 5 Pt 1 (1997) 432-437